← All trials
NCT05883306
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Jul 21, 2022
- Completion date
- Dec 23, 2022
- First posted
- May 31, 2023
- Last posted
- May 31, 2023
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.Lead sponsor
- Soochow UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.